2020 Announcements Clinical
Australian TGA commences SCENESSE® review
EXECUTIVE SUMMARY
- SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare disease EPP
- Priority Review aims at a technology review timeframe of 150 working days
- Advisory Committee on Medicines may be required during the review of SCENESSE®